Overview

A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Status:
Not yet recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose and multiple-dose of DBPR108 tablets in Type 2 Diabetes Mellitus Patients.

Phase:

Phase 1

Details

Lead Sponsor:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.